Business Context and Reporting Period
This Form 8-K is a current report filed by AcelRx Pharmaceuticals, Inc. (not TalpherA, Inc., as noted in the metadata request) on August 12, 2011, regarding events occurring on August 11, 2011. The filing serves to announce the Company's financial results for the quarter ended June 30, 2011, via a press release furnished as Exhibit 99.1.
Key Financial Metrics
The filing text provided does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being contained within the press release (Exhibit 99.1) but are not detailed in the body of this Form 8-K.
Material Changes
The filing does not provide specific data to compare current period performance against prior comparable periods. It solely references the issuance of the press release containing the quarterly results.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer stating that the information in Item 2.02 and the accompanying press release shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934. Consequently, this information is not subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, nor will it be incorporated by reference into any other SEC filings by the Company.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated August 11, 2011) for actual financial figures, as they are absent from the Form 8-K text.
- Verify the registrant name is AcelRx Pharmaceuticals, Inc., not TalpherA, Inc.
- Note that the financial data in this filing is not incorporated by reference into future SEC filings.
- Confirm the reporting period is the quarter ended June 30, 2011.